Ivonescimab
HARMONi Phase 3: Ivonescimab Confirms PFS Benefit; OS Primary Endpoint Not Met, Nominal in Follow-Up Analysis
Summit Therapeutics’ Ivonescimab demonstrates statistically significant PFS improvement in the global HARMONi trial. OS did not meet the pre-specified threshold in the primary analysis, but longer follow-up in Western patients shows a nominal supportive trend for regulatory review.